Masimo (NASDAQ:MASI) is a global medical technology company specializing in noninvasive patient monitoring solutions. Its core business centers on advanced pulse oximetry and related monitoring technologies designed to improve patient care across a variety of clinical settings. Masimo’s products are used in hospitals, ambulatory surgery centers, physician offices and home health environments, providing continuous, accurate monitoring of vital signs without the need for invasive procedures.
The company’s product portfolio includes Masimo SET® pulse oximetry, rainbow® Pulse CO-Oximetry™, acoustic respiration rate monitoring, noninvasive hemoglobin measurement, and regional oximetry devices. In addition, Masimo offers integrated monitoring platforms that combine multiple patient parameters into a single display, along with wireless connectivity solutions for remote patient surveillance and data analytics. Masimo’s technology is also incorporated into consumer health devices aimed at home wellness tracking and telehealth applications.
Founded in 1989 by electrical engineer Joe E. Kiani, Masimo introduced its first pulse oximetry system in 1995 and completed its initial public offering in 2007. Headquartered in Irvine, California, the company maintains research and development centers, manufacturing facilities and customer support offices in the United States, Europe and Asia. Masimo continues to invest in innovation, holding hundreds of patents on noninvasive monitoring technologies.
Under the leadership of Chairman and CEO Joe E. Kiani, Masimo serves healthcare providers and patients in over 100 countries. Its products are used in critical care, perioperative, neonatal and remote monitoring applications, helping clinicians detect changes in patient status earlier and improve clinical outcomes. Masimo also collaborates with leading medical device companies to integrate its monitoring technologies into a broad spectrum of healthcare platforms worldwide.
